Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Stock Report: Organovo Holdings, Inc. (ONVO) Report Updated: Oct 13, 2018 | Print This Page

Get more stock ratings by Louis Navellier

Organovo Holdings, Inc. (ONVO)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Organovo Holdings, Inc.© quotemedia

Company Profile

Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. It is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair, and functional tissue patches for the repair or replacement of damaged tissues and organs. The company has a collaboration agreement with Merck Sharp & Dohme Corp. (Merck). that provides Merck access to the company’s commercial exVive3D human liver tissue service, as well as to develop multiple custom tissue models. Organovo Holdings, Inc. was founded in 2007 and is based in San Diego, California.